These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1679210)

  • 21. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
    Meller E; Goldstein M; Bohmaker K
    Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice.
    Abe M; Nakai H; Tabata R; Saito K; Egawa M
    Jpn J Pharmacol; 1998 Mar; 76(3):297-304. PubMed ID: 9593223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tandospirone in three behavioral tests for anxiolytics.
    Pollard GT; Nanry KP; Howard JL
    Eur J Pharmacol; 1992 Oct; 221(2-3):297-305. PubMed ID: 1358655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites.
    Hamik A; Oksenberg D; Fischette C; Peroutka SJ
    Biol Psychiatry; 1990 Jul; 28(2):99-109. PubMed ID: 1974152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonergic anxiolytics and treatment of depression.
    Robinson DS; Alms DR; Shrotriya RC; Messina M; Wickramaratne P
    Psychopathology; 1989; 22 Suppl 1():27-36. PubMed ID: 2657837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
    de Boer SF; Lesourd M; Mocaer E; Koolhaas JM
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1125-33. PubMed ID: 10027850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hippocampal neurons.
    Bockaert J; Dumuis A; Bouhelal R; Sebben M; Cory RN
    Naunyn Schmiedebergs Arch Pharmacol; 1987 May; 335(5):588-92. PubMed ID: 2886925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 5-HT1A selective anxiolytics on lordosis behavior: interactions with progesterone.
    Mendelson SD; Gorzalka BB
    Eur J Pharmacol; 1986 Dec; 132(2-3):323-6. PubMed ID: 2880737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A risk-benefit assessment of buspirone in the treatment of anxiety disorders.
    Pecknold JC
    Drug Saf; 1997 Feb; 16(2):118-32. PubMed ID: 9067123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?].
    Davids E; Lesch KP
    Fortschr Neurol Psychiatr; 1996 Nov; 64(11):460-72. PubMed ID: 9064274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission.
    Blier P; Curet O; Chaput Y; de Montigny C
    Neuropharmacology; 1991 Jul; 30(7):691-701. PubMed ID: 1681447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alcohol and drug interactions with antianxiety medications.
    Schuckit MA
    Am J Med; 1987 May; 82(5A):27-33. PubMed ID: 2884873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical profile of buspirone.
    Knapp JE
    Br J Clin Pract Suppl; 1985 May; 38():95-9. PubMed ID: 2862910
    [No Abstract]   [Full Text] [Related]  

  • 35. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
    Goa KL; Ward A
    Drugs; 1986 Aug; 32(2):114-29. PubMed ID: 2874976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HT1A agonist effects on punished responding of squirrel monkeys.
    Gleeson S; Barrett JE
    Pharmacol Biochem Behav; 1990 Oct; 37(2):335-7. PubMed ID: 1981937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder.
    Cutler NR; Hesselink JM; Sramek JJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 May; 18(3):447-63. PubMed ID: 7915845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological and clinical effects of buspirone.
    Taylor DP; Eison MS; Riblet LA; Vandermaelen CP
    Pharmacol Biochem Behav; 1985 Oct; 23(4):687-94. PubMed ID: 2866549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buspirone: review of its pharmacology and current perspectives on its mechanism of action.
    Eison AS; Temple DL
    Am J Med; 1986 Mar; 80(3B):1-9. PubMed ID: 2870639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The actions of diazepam and serotonergic anxiolytics vary according to the gender and the estrous cycle phase.
    Fernández-Guasti A; Picazo O
    Pharmacol Biochem Behav; 1990 Sep; 37(1):77-81. PubMed ID: 1979876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.